Sensorium Therapeutics
Michael Placzek has a long history of work experience in the medical field. Michael began their career in 2006 as an Analytical Chemistry Technician II at Microtest Laboratories. In 2012, they were a Visiting Scientist at SciFluor Life Sciences, LLC, where they assisted the Imaging department in the synthesis and radiolabeling of fluorine labeled positron emission tomography (PET) agents. In 2013, they began working at Harvard Medical School as an Assistant Professor of Radiology, an Instructor in Radiology, an Instructor in Psychiatry, and a Postdoctoral Research Fellow with an NIH-NIDA Ruth L. Kirschstein T32 postdoctoral fellowship. In 2015, they became a Postdoctoral Research Fellow at McLean Hospital with an NIH-NIDA Ruth L. Kirschstein T32 postdoctoral fellowship. In 2017, they became a Research Faculty at The MGH/HST Martinos Center for Biomedical Imaging. In 2019, they became the Director of Pharmacology at the Martinos Center Chemical Neuroscience Program. Most recently, in 2022, they became the Director of Drug Discovery at Sensorium Therapeutics.
Michael Placzek obtained a Bachelor of Science (BS) in Chemistry from College of Our Lady of the Elms between 2002 and 2006. Michael then went on to earn a Doctor of Philosophy (PhD) in Organic Chemistry from Northeastern University between 2008 and 2013.
This person is not in any teams
Sensorium Therapeutics
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world.